Product Description
Alitretinoin is a first generation member of the retinoid family, which also includes retinol, retinal, tretinoin, isotretinoin and acitretin. The retinoids are all related to Vitamin A. (Sourced from: https://dermnetnz.org/topics/alitretinoin)
Mechanisms of Action: RXR Agonist, RAR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Bulgaria | Canada | Chile | Denmark | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Lithuania | Malta | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/02/2025 |
News Article |
Anzupgo® (delgocitinib cream) Now Available in Canada for Adult Patients Living with Moderate to Severe Chronic Hand Eczema |
|
12/02/2025 |
News Article |
/C O R R E C T I O N -- LEO Pharma/ |
|
11/05/2025 |
News Article |
LEO Pharma Announces NICE Recommendation of Reimbursement in England and Wales |
|
10/16/2025 |
News Article |
LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China |